Your browser doesn't support javascript.
loading
Claudin-5-Binders Enhance Permeation of Solutes across the Blood-Brain Barrier in a Mammalian Model.
Hashimoto, Yosuke; Shirakura, Keisuke; Okada, Yoshiaki; Takeda, Hiroyuki; Endo, Kohki; Tamura, Maki; Watari, Akihiro; Sadamura, Yoshifusa; Sawasaki, Tatsuya; Doi, Takefumi; Yagi, Kiyohito; Kondoh, Masuo.
Afiliação
  • Hashimoto Y; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Shirakura K; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Okada Y; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Takeda H; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Endo K; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Tamura M; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Watari A; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Sadamura Y; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Sawasaki T; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Doi T; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Yagi K; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.).
  • Kondoh M; Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan (Y.H., K.S., Y.O., A.W., T.D., K.Y., M.K.); Proteo-Science Center, Ehime University, Ehime, Japan (H.T., T.S.); and Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan (K.E., M.T., Y.S.) masu
J Pharmacol Exp Ther ; 363(2): 275-283, 2017 11.
Article em En | MEDLINE | ID: mdl-28819070
ABSTRACT
A current bottleneck in the development of central nervous system (CNS) drugs is the lack of drug delivery systems targeting the CNS. The intercellular space between endothelial cells of the blood-brain barrier (BBB) is sealed by complex protein-based structures called tight junctions (TJs). Claudin-5 (CLDN-5), a tetra-transmembrane protein is a key component of the TJ seal that prevents the paracellular diffusion of drugs into the CNS. In the present study, to investigate whether CLDN-5 binders can be used for delivery of drugs to the CNS, we generated monoclonal antibodies (mAbs) specific to the extracellular domains of CLDN-5. In an in vitro model of the BBB, the anti-CLDN-5 mAbs attenuated trans-epithelial/endothelial electrical resistance and enhanced solute permeation. These anti-CLDN-5 mAbs are potential leads for the development of novel drug delivery systems targeting the CNS.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Barreira Hematoencefálica / Claudina-5 Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Barreira Hematoencefálica / Claudina-5 Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article